Welcome to our dedicated page for ONCOLYTICS BIOTECH SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncolytics Biotech filings document a clinical-stage oncology company developing pelareorep and reporting material events through Form 8-K disclosures. Recent filings cover pelareorep study updates in metastatic colorectal cancer and squamous cell anal carcinoma, FDA-related development communications, translational data presented from GOBLET and AWARE-1, and incorporation of certain exhibits into a Form F-3 registration statement.
The company's regulatory record also documents capital-structure matters, including Nasdaq-listed ONCY common stock and an open-market sale agreement, as well as corporate-status changes tied to its completed continuance and domestication from Canadian jurisdictions to Nevada. These filings describe governance approvals, registered securities, financing arrangements, and oncology development disclosures for the issuer.
Oncolytics Biotech Inc. filed a report stating that on February 4, 2026 it issued a press release announcing that the U.S. Food and Drug Administration granted Fast Track Designation for a drug combination including pelareorep, bevacizumab, leucovorin, fluorouracil, and irinotecan (FOLFIRI) in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer.
The company also states that this report, including the press release attached as Exhibit 99.1, is incorporated by reference as an exhibit to its Registration Statement on Form F-3 (File No. 333-289819).
Oncolytics Biotech Inc. director Bernd R. Seizinger reported buying additional common shares of the company. On January 16, 2026, he acquired 100,000 common shares of Oncolytics Biotech at a weighted average price of $1.0377 per share, through multiple trades executed between $1.0294 and $1.0499.
Following this purchase, Seizinger beneficially owns 466,991 common shares, held directly. The filing notes that full detail on the number of shares bought at each individual price within the stated range is available upon request from the company, any security holder, or the SEC staff.
Oncolytics Biotech Inc. held a Special Meeting of Shareholders on January 15, 2026, where investors voted on key corporate changes. Shareholders representing 17,596,480 common shares, or 16.35% of the 107,606,376 shares outstanding as of the December 9, 2025 record date, were present or represented by proxy.
Investors approved a special resolution to continue the company from the Province of Alberta to the Province of British Columbia, and another special resolution to then domesticate the company from British Columbia to the State of Nevada in the United States. They also approved the Oncolytics Biotech Inc. 2026 Incentive Award Plan, each proposal receiving more votes for than against.
The company later issued a press release announcing these results, which has been filed as an exhibit and incorporated by reference into its Form F-3 registration statement.
Oncolytics Biotech, Inc. filed a current report to disclose leadership changes. The company announced that John McAdory has been appointed as Executive Vice President of Strategy and Operations and Yujun Wu has been appointed as Vice President, Head of Biostatistics, signaling additions to its senior management team.
The company also states that this report on Form 8-K, including the attached press release, is incorporated by reference as an exhibit to its Registration Statement on Form F-3 (File No. 333-289819). No financial results or major transactions are described in this report.
Oncolytics Biotech, Inc. filed a Form 8-K to highlight two recent developments related to its cancer therapy pelareorep. On January 8, 2026, the company issued a press release describing updates to its intellectual property portfolio and efforts to extend patent protection for pelareorep as part of its long-term value and development strategy. On January 12, 2026, it released updated clinical data from the GOBLET Cohort 4 study, which showed activity of pelareorep combined with atezolizumab in third-line anal cancer.
The company is also using this report, including the two press releases attached as Exhibits 99.1 and 99.2, as an exhibit to its existing shelf Registration Statement on Form F-3. This helps ensure that the patent and clinical updates are formally included in the broader disclosure framework the company uses for potential future securities offerings.
Oncolytics Biotech Inc. filed a Form 6-K that includes a press release announcing three new members to its gastrointestinal Tumor Scientific Advisory Board: Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris. These globally recognized GI oncologists will advise on the development of pelareorep, the company’s investigational immunotherapy, across pancreatic, colorectal, and anal cancers.
The company highlights aggregated clinical data suggesting higher overall survival and response rates for pelareorep-based regimens versus historical benchmarks in first-line pancreatic cancer, squamous cell anal carcinoma, and KRAS-mutant metastatic colorectal cancer. Oncolytics states it is planning pivotal studies in all three indications, intends to continue engaging with the FDA where needed, and notes that its metastatic pancreatic and breast cancer programs with pelareorep have received Fast Track designation.